Retrieve available abstracts of 324 articles: HTML format
Single Articles
June 2025
CHEN C, Xu J, Sussman JH, Vincent T, et al Single-cell panleukemia signatures of HSPC-like blasts predict drug response and
clinical outcome.
Blood. 2025;145:2685-2700. PubMedAbstract available
KATER AP, Harrup R, Kipps TJ, Eichhorst B, et al The MURANO study: final analysis and retreatment/crossover substudy results of
VenR for patients with relapsed/refractory CLL.
Blood. 2025;145:2733-2745. PubMedAbstract available
WIERDA WG, Eichhorst BF, Hallek MJ Hitting the Therapeutic Bullseye with Targeted Therapy for Patients with Chronic
Lymphocytic Leukemia.
Blood. 2025 Jun 2:blood.2025028570. doi: 10.1182/blood.2025028570. PubMedAbstract available
May 2025
LU J, Xue SL, Wang Y, He XF, et al Venetoclax and decitabine vs intensive chemotherapy as induction for young
patients with newly diagnosed AML.
Blood. 2025;145:2645-2655. PubMedAbstract available
EGAN G, Tasian SK Precision medicine for high-risk gene fusions in pediatric AML: a focus on KMT2A,
NUP98, and GLIS2 rearrangements.
Blood. 2025;145:2574-2586. PubMedAbstract available
ESCHERICH CS, Li Z, Barnett KR, Li Y, et al Differentiation-dependent EBF1 Activity Determines CD22 Transcription and
Leukemia Sensitivity to Inotuzumab Ozogamicin.
Blood. 2025 May 28:blood.2024028215. doi: 10.1182/blood.2024028215. PubMedAbstract available
MAYDAY MY, Biancon G, Wei M, Ramirez C, et al RBM15-MKL1 fusion protein promotes leukemia via m6A methylation and WNT pathway
activation.
Blood. 2025 May 28:blood.2024027712. doi: 10.1182/blood.2024027712. PubMedAbstract available
JUM'AH H, Viswanatha D Classic hairy cell leukemia and concomitant smoldering myeloma.
Blood. 2025;145:2533. PubMed
BASSAN R, Chiaretti S, Della Starza I, Santoro A, et al Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage
ALL: the GIMEMA LAL2317 phase 2 study.
Blood. 2025;145:2447-2459. PubMedAbstract available
YOSHIMITSU M, Choi I, Kusumoto S, Shimokawa M, et al A phase 2 Trial of CHOP with Anti-CCR4 Antibody Mogamulizumab for older Patients
with Adult T-Cell Leukemia/Lymphoma.
Blood. 2025 May 15:blood.2024027902. doi: 10.1182/blood.2024027902. PubMedAbstract available
WANG X, Yi H Adult T-cell leukemia/lymphoma coexistent with immune dysregulation-associated
EBV+ lymphoproliferative disorder.
Blood. 2025;145:2396. PubMed
SAORIN A, Dehler A, Galvan B, Steffen FD, et al Transcriptional remodeling shapes therapeutic vulnerability to necroptosis in
acute lymphoblastic leukemia.
Blood. 2025 May 13:blood.2025028938. doi: 10.1182/blood.2025028938. PubMedAbstract available
ALDOSS I, Clark MC, Forman SJ How I Treat: Revisiting the myth of second remission in acute lymphoblastic
leukemia in the era of immunotherapy.
Blood. 2025 May 12:blood.2024027267. doi: 10.1182/blood.2024027267. PubMedAbstract available
HOURIGAN CS From prognostication to precision in acute myeloid leukemia.
Blood. 2025;145:2105-2106. PubMed
Luskin MR, Murakami MA, Keating J, et al. Asciminib plus dasatinib and prednisone
for Philadelphia chromosome-positive acute leukemia. Blood. 2025;145(6):577-589.
Blood. 2025;145:2231. PubMed
LEVIS MJ, Hamadani M, Logan BR, Jones RJ, et al Measurable residual disease and posttransplantation gilteritinib maintenance for
patients with FLT3-ITD-mutated AML.
Blood. 2025;145:2138-2148. PubMedAbstract available
GOOPTU M, Murdock HM, Soiffer RJ How I treat AML relapse after allogeneic HSCT.
Blood. 2025;145:2128-2137. PubMedAbstract available
TEFFERI A, Fathima S, Abdelmagid M, Alsugair A, et al BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic
Myelomonocytic Leukemia.
Blood. 2025 May 7:blood.2024027170. doi: 10.1182/blood.2024027170. PubMedAbstract available
ARELLANO ML, Thirman MJ, DiPersio JF, Heiblig M, et al Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute
myeloid leukemia: the AUGMENT-101 study.
Blood. 2025 May 7:blood.2025028357. doi: 10.1182/blood.2025028357. PubMedAbstract available
BULLINGER L Mixed-phenotype acute leukemia revisited: omics lead the way.
Blood. 2025;145:1969-1971. PubMed
April 2025
MCMAHON CM Beyond conVENtional 7+3 in acute myeloid leukemia.
Blood. 2025;145:1831-1832. PubMed
GARCIAZ S STINGing leukemia stem cells through PSTK inhibition.
Blood. 2025;145:1833-1835. PubMed
ZHANG W, Cai J, Wang X, Ma Y, et al Prognostic and therapeutic implications of measurable residual disease levels
during remission induction of childhood ALL.
Blood. 2025;145:1890-1902. PubMedAbstract available
PODVIN B, Hardeman A Early T-precursor acute lymphoblastic leukemia with mature plasmacytoid dendritic
cell proliferation.
Blood. 2025;145:1827. PubMed
CHAKRABORTY SR, Karrs JX A rare case of nodal hairy cell leukemia exhibiting characteristic morphological
and immunohistochemical features.
Blood. 2025;145:1826. PubMed
DE KESEL J, Fijalkowski I, Pieters T, Borin C, et al HNRNPC and m6A RNA methylation control oncogenic transcription and metabolism in
T-cell leukemia.
Blood. 2025 Apr 15:blood.2024026848. doi: 10.1182/blood.2024026848. PubMedAbstract available
DAVIDS MS, Kenderian SS, Flinn IW, Hill BT, et al ZUMA-8: A Phase 1 Study of Brexucabtagene Autoleucel in Patients With
Relapsed/Refractory Chronic Lymphocytic Leukemia.
Blood. 2025 Apr 10:blood.2024027460. doi: 10.1182/blood.2024027460. PubMedAbstract available
TURHAN AG SMAC mimetics in action in chronic myeloid leukemia.
Blood. 2025;145:1596-1597. PubMed
Zhu H-H, Hu J, Lo-Coco F, Jin J. The simpler, the better: oral arsenic for acute
promyelocytic leukemia. Blood. 2019;134(7):597-605.
Blood. 2025;145:1703-1705. PubMed
SILBERT SK, Rankin AW, Hoang CN, Semchenkova A, et al Project EVOLVE: An international analysis of postimmunotherapy lineage switch, an
emergent form of relapse in leukemia.
Blood. 2025 Apr 7:blood.2024026655. doi: 10.1182/blood.2024026655. PubMedAbstract available
DOMBRET H Introduction to a review series on acute lymphoblastic leukemia.
Blood. 2025;145:1439. PubMed
RAMPOTAS A, Roddie C The present and future of CAR T-cell therapy for adult B-cell ALL.
Blood. 2025;145:1485-1497. PubMedAbstract available
March 2025
BAKHSHI TJ, Pina-Oviedo S Warthin-Finkeldey cells seen in a setting other than measles: chronic lymphocytic
leukemia/small lymphocytic lymphoma.
Blood. 2025;145:1437. PubMed
CALO-PEREZ A, Martinez-Fernandez R Atypical chronic myeloid leukemia: from cytology to molecular characterization.
Blood. 2025;145:1438. PubMed
ROTHFUSS C, Baumann T, Donakonda S, Brauchle B, et al Two-layered immune escape in AML is overcome by Fcgamma receptor activation and
inhibition of PGE2 signaling in NK cells.
Blood. 2025;145:1395-1406. PubMedAbstract available
HAN Q, Gu Y, Xiang H, Zhang L, et al Targeting WDR5/ATAD2 signaling by the CK2/IKAROS axis demonstrates therapeutic
efficacy in T-ALL.
Blood. 2025;145:1407-1421. PubMedAbstract available
CHEN J, Suttorp M, Hijiya N How I treat chronic myeloid leukemia in children and adolescents.
Blood. 2025 Mar 25:blood.2024026514. doi: 10.1182/blood.2024026514. PubMedAbstract available
KOTROVA M, Proske C, Darzentas N, Laqua A, et al NGS-based IG/TR rearrangement profiling in acute lymphoblastic leukemia: age
dependence of immunogenetic maturation.
Blood. 2025 Mar 25:blood.2024027175. doi: 10.1182/blood.2024027175. PubMedAbstract available
LUGER SM Introduction to a How I Treat series on acute myeloid leukemia.
Blood. 2025;145:1227-1228. PubMed
FURSTENAU M, Robrecht S, Schneider C, Tausch E, et al MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary
end point analysis from the CLL2-BZAG trial.
Blood. 2025;145:1282-1292. PubMedAbstract available
WEI AH, Loo S, Daver N How I treat patients with AML using azacitidine and venetoclax.
Blood. 2025;145:1237-1250. PubMedAbstract available
LUO Q, Fortune AL, Lane AA PI3Kgamma in leukemia: class IB PI3 kinase reemerges as a cancer-intrinsic target.
Blood. 2025 Mar 19:blood.2024027376. doi: 10.1182/blood.2024027376. PubMedAbstract available
XU J, Sussman JH, Yang A, Yoshimura S, et al STAT1-mediated interferon signatures associate with preclinical JAK-inhibitor
sensitivity in T-cell acute lymphoblastic leukemia.
Blood. 2025 Mar 18:blood.2025028566. doi: 10.1182/blood.2025028566. PubMedAbstract available
DALGETTY M, Cortes J Considerations on the Dose and Schedule of Tyrosine Kinase Inhibitors for Chronic
Myeloid Leukemia: Does Dose Matter?
Blood. 2025 Mar 18:blood.2024027944. doi: 10.1182/blood.2024027944. PubMedAbstract available
FALGAS A, Lazaro-Gorines R, Zanetti SR, Rubio-Perez L, et al A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR-T cell therapy
in B-cell acute lymphoblastic leukemia.
Blood. 2025 Mar 16:blood.2024025440. doi: 10.1182/blood.2024025440. PubMedAbstract available
WANG WJ, Loghavi S Acute myeloid leukemia with RUNX1::CBFA2T3 fusion.
Blood. 2025;145:1226. PubMed
WULIJI N, Jones SMW, Gooley TA, Gerds AT, et al Social Determinants of Health and Access to Allogeneic Hematopoietic Cell
Transplantation for Acute Myeloid Leukemia.
Blood. 2025 Mar 11:blood.2024027543. doi: 10.1182/blood.2024027543. PubMedAbstract available
TAM CS, Balendran S, Blombery P Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation
and noncovalent BTK inhibitors.
Blood. 2025;145:1005-1009. PubMedAbstract available
February 2025
ZEIDNER JF, Sallman DA, Recher C, Daver NG, et al Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated
acute myeloid leukemia: the ENHANCE-2 study.
Blood. 2025 Feb 26:blood.2024027408. doi: 10.1182/blood.2024027408. PubMedAbstract available
TAMIRO F, Padovano C, De Santis E, Di Iasio S, et al NOTCH1 dimeric signaling is essential for T-cell leukemogenesis and leukemia
maintenance.
Blood. 2025 Feb 26:blood.2024027020. doi: 10.1182/blood.2024027020. PubMedAbstract available
CONDOLUCI A, Romano I, Dietrich D, Pini K, et al Ibrutinib Lead-in followed by Venetoclax Plus Ibrutinib in Relapsed/Refractory
Chronic Lymphocytic Leukemia - SAKK 34/17.
Blood. 2025 Feb 26:blood.2024026879. doi: 10.1182/blood.2024026879. PubMedAbstract available
ALLEN B, Bottomly D, Kohnke T, Wang A, et al A CEBPB/IL-1beta/TNF-alpha Feedback Loop Drives Drug Resistance to Venetoclax and MDM2
Inhibitors in Monocytic Leukemia.
Blood. 2025 Feb 26:blood.2024028239. doi: 10.1182/blood.2024028239. PubMedAbstract available
LINDER A, Nixdorf D, Kuhl N, Piseddu I, et al STING activation improves T-cell-engaging immunotherapy for acute myeloid
leukemia.
Blood. 2025 Feb 26:blood.2024026934. doi: 10.1182/blood.2024026934. PubMedAbstract available
AL JABRI M, Chang H Blastoid variant of double-hit lymphoma masquerading as acute lymphoblastic
leukemia.
Blood. 2025;145:897. PubMed
PARISI X, Loghavi S Acute erythroid leukemia or acute myeloid leukemia with mutated TP53? The battle
of phenotype versus genotype.
Blood. 2025;145:784. PubMed
SHAH V, Giotopoulos G, Osaki H, Meyerhofer M, et al Acute resistance to BET inhibitors remodels compensatory transcriptional programs
via p300 coactivation.
Blood. 2025;145:748-764. PubMedAbstract available
SILVA HJ, Martin G, Birocchi F, Wehrli M, et al CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome
antigen heterogeneity in AML.
Blood. 2025;145:720-731. PubMedAbstract available
MANTZARIS I, Goldfinger M, Uriel M, Shastri A, et al Venetoclax plus Daunorubicin and Cytarabine for Newly Diagnosed Acute Myeloid
Leukemia: Results of a Phase 1b Study.
Blood. 2025 Feb 7:blood.2024026700. doi: 10.1182/blood.2024026700. PubMedAbstract available
SHEN Q, Hu S Acute myeloid leukemia with BCL6 and KMT2A dual rearrangements.
Blood. 2025;145:652. PubMed
FISKUS W, Mill CP, Bose P, Masarova L, et al Preclinical efficacy of CDK7 inhibitor-based combinations against
myeloproliferative neoplasms transformed to AML.
Blood. 2025;145:612-624. PubMedAbstract available
HE L, Zhao T, Leong WZ, Sharda A, et al PSTK inhibition activates cGAS-STING, precipitating ferroptotic cell death in
leukemic stem cells.
Blood. 2025 Feb 5:blood.2024026040. doi: 10.1182/blood.2024026040. PubMedAbstract available
January 2025
LYAPICHEV KA, Behdad A c-MYC stain as a potential minimal residual disease marker for acute myeloid
leukemia with NPM1 mutation.
Blood. 2025;145:547. PubMed
POHLY MF, Putzker K, Scheinost S, Ben Taarit L, et al IAP dependency of T-cell prolymphocytic leukemia identified by high-throughput
drug screening.
Blood. 2025 Jan 27:blood.2024027171. doi: 10.1182/blood.2024027171. PubMedAbstract available
ABEDIN SM, Uy GL, Michaelis LC The Fit Older Adult with Acute Myeloid Leukemia: Clinical Challenges to Providing
Evidence-Based Frontline Treatment.
Blood. 2025 Jan 24:blood.2024026004. doi: 10.1182/blood.2024026004. PubMedAbstract available
CHAPAPRIETA V, Maiques-Diaz A, Nadeu F, Clot G, et al Dual Biological Role and Clinical Impact of De Novo Chromatin Activation in
Chronic Lymphocytic Leukemia.
Blood. 2025 Jan 22:blood.2024025396. doi: 10.1182/blood.2024025396. PubMedAbstract available
ALIKARAMI F, Xie HM, Riedel SS, Goodrow H, et al GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia.
Blood. 2025 Jan 22:blood.2024025761. doi: 10.1182/blood.2024025761. PubMedAbstract available
LYU J, Liu Y, Liu N, Vu H, et al CD44-Mediated Metabolic Rewiring is A Targetable Dependency of IDH-Mutant
Leukemia.
Blood. 2025 Jan 22:blood.2024027207. doi: 10.1182/blood.2024027207. PubMedAbstract available
SCHAFER HACKENHAAR F, Refhagen N, Hagleitner MM, van Leeuwen FN, et al CpG island methylator phenotype classification improves risk assessment in
pediatric T-cell Acute Lymphoblastic Leukemia.
Blood. 2025 Jan 22:blood.2024026027. doi: 10.1182/blood.2024026027. PubMedAbstract available
ARAUJO JL, Wagenblast E, Voisin V, McLeod J, et al FLT3 is genetically essential for ITD-mutated leukemic stem cells but dispensable
for human hematopoietic stem cells.
Blood. 2025 Jan 22:blood.2024025886. doi: 10.1182/blood.2024025886. PubMedAbstract available
GALERA P, Dilip D, Derkach A, Chan A, et al Defining 2 Biologically and Clinically Distinct Groups in Acute Leukemia with a
Mixed Phenotype.
Blood. 2025 Jan 15:blood.2024026273. doi: 10.1182/blood.2024026273. PubMedAbstract available
RONNACKER J, Grau M, Klasmeier M, Klesse C, et al Common Hereditary Variants of the APOE Gene and Posttransplant Outcome in Acute
Myeloid Leukemia.
Blood. 2025 Jan 15:blood.2024026886. doi: 10.1182/blood.2024026886. PubMedAbstract available
NYGREN PJ, Bouhlal JOV, Jokinen E, Forsten S, et al High-throughput drug screening identifies SMAC mimetics as enhancers of NK cell
cytotoxicity in chronic myeloid leukemia.
Blood. 2025 Jan 10:blood.2024025286. doi: 10.1182/blood.2024025286. PubMedAbstract available
PURVIS K, Zhou Y, Karol SE, Rubnitz JE, et al Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the
St. Jude Total Therapy XV/XVI studies.
Blood. 2025;145:190-201. PubMedAbstract available
DING YY, Sussman JH, Madden K, Loftus JP, et al Targeting Senescent Stemlike Subpopulations in Philadelphia Chromosome-Like Acute
Lymphoblastic Leukemia.
Blood. 2025 Jan 7:blood.2024026482. doi: 10.1182/blood.2024026482. PubMedAbstract available
BASKAR S, Peng H, Gaglione EM, Carstens EJ, et al Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragment
covalently deposited on lymphoma cells.
Blood. 2025 Jan 7:blood.2024024846. doi: 10.1182/blood.2024024846. PubMedAbstract available
DOMBRET H Introduction to a How I Treat series on acute lymphoblastic leukemia.
Blood. 2025;145:1-2. PubMed
CHIARETTI S, Foa R How I treat adult Ph+ ALL.
Blood. 2025;145:11-19. PubMedAbstract available
LAMBLE AJ, Kovach AE, Shah NN How I treat postimmunotherapy relapsed B-ALL.
Blood. 2025;145:64-74. PubMedAbstract available
December 2024
PASSET M, Kim R, Clappier E Genetic subtypes of B-cell acute lymphoblastic leukemia in adults.
Blood. 2024 Dec 30:blood.2023022919. doi: 10.1182/blood.2023022919. PubMedAbstract available
CRUZ-RODRIGUEZ N, Deininger MW Novel Treatment Strategies for Chronic Myeloid Leukemia.
Blood. 2024 Dec 27:blood.2024026312. doi: 10.1182/blood.2024026312. PubMedAbstract available
ESCHERICH CS, Moriyama T, Li Z, Hsiao Y, et al DNTT-mediated DNA Damage Response Drives Inotuzumab Ozogamicin Resistance in
B-cell Acute Lymphoblastic Leukemia.
Blood. 2024 Dec 27:blood.2024026085. doi: 10.1182/blood.2024026085. PubMedAbstract available
MILLMAN SE, Chaves-Perez A, Janaki-Raman S, Ho YJ, et al alpha-Ketoglutarate dehydrogenase is a therapeutic vulnerability in acute myeloid
leukemia.
Blood. 2024 Dec 27:blood.2024025245. doi: 10.1182/blood.2024025245. PubMedAbstract available
NAHARRO EF, Linden MA Auer rod-like inclusions in B-cell lymphoma mimicking therapy-related acute
myeloid leukemia.
Blood. 2024;144:2793. PubMed
LACHOWIEZ CA, Ravikumar VI, Othman J, O'Nions J, et al Refined ELN 2024 risk stratification improves survival prognostication following
venetoclax-based therapy in AML.
Blood. 2024;144:2788-2792. PubMedAbstract available
BROWN JR, Eichhorst B, Lamanna N, O'Brien SM, et al Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL:
final comparative analysis of ALPINE.
Blood. 2024;144:2706-2717. PubMedAbstract available
HULS GA, Woolthuis CM, Schuringa JJ Menin inhibitors in the treatment of acute myeloid leukemia.
Blood. 2024 Dec 24:blood.2024026232. doi: 10.1182/blood.2024026232. PubMedAbstract available
ARONS E, Tai CH, Suraj J, Liu Y, et al Non-V600E BRAF mutations and treatment for Hairy Cell Leukemia.
Blood. 2024 Dec 24:blood.2024026894. doi: 10.1182/blood.2024026894. PubMedAbstract available
CUI B, Ai L, Lei M, Duan Y, et al Single-cell epigenetic and clonal analysis decodes disease progression in
pediatric acute myeloid leukemia.
Blood. 2024 Dec 11:blood.2024025618. doi: 10.1182/blood.2024025618. PubMedAbstract available
BOUDIA F, Baille M, Babin L, Aid Z, et al Progressive chromatin rewiring by ETO2::GLIS2 revealed in a human iPSC model of
pediatric leukemia initiation.
Blood. 2024 Dec 10:blood.2024024505. doi: 10.1182/blood.2024024505. PubMedAbstract available
HAUBNER S, Subklewe M, Sadelain M Honing CAR T cells to tackle acute myeloid leukemia.
Blood. 2024 Dec 4:blood.2024024063. doi: 10.1182/blood.2024024063. PubMedAbstract available
November 2024
GOLDFINGER M, Mantzaris I, Shastri A, Saunthararajah Y, et al A weekly low-dose regimen of decitabine and venetoclax is efficacious and less
myelotoxic in a racially diverse cohort.
Blood. 2024;144:2360-2363. PubMedAbstract available
DOHNER H, DiNardo CD, Appelbaum FR, Craddock C, et al Genetic risk classification for adults with AML receiving less-intensive
therapies: the 2024 ELN recommendations.
Blood. 2024;144:2169-2173. PubMedAbstract available
DOHNER H, Pratz KW, DiNardo CD, Wei AH, et al Genetic risk stratification and outcomes among treatment-naive patients with AML
treated with venetoclax and azacitidine.
Blood. 2024;144:2211-2222. PubMedAbstract available
MA J, Wang Z, Mintzlaff D, Zhang H, et al Bivalent CD47 Immunotoxin for Targeted Therapy of T-Cell Acute Lymphoblastic
Leukemia.
Blood. 2024 Nov 19:blood.2024025277. doi: 10.1182/blood.2024025277. PubMedAbstract available
NAIR MS, Silbert SK, Rejeski K, Wilson KA, et al Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity
in B-cell acute lymphoblastic leukemia.
Blood. 2024 Nov 19:blood.2024025910. doi: 10.1182/blood.2024025910. PubMedAbstract available
LU P, Zhang X, Yang J, Li J, et al Nanobody-based Naturally Selected CD7-Targeted CAR-T Therapy for Acute Myeloid
Leukemia.
Blood. 2024 Nov 19:blood.2024024861. doi: 10.1182/blood.2024024861. PubMedAbstract available
Handa S, Lee J-O, Derkach A, et al. Long-term outcomes in patients with relapsed
or refractory hairy cell leukemia treated with vemurafenib monotherapy. Blood.
2022;140(25):2663-2671.
Blood. 2024;144:2068. PubMed
CHEVALIER S, Legrand C B-cell acute lymphoblastic leukemia with MEF2D::BCL9 rearrangement mimicking a
Burkitt lymphoma.
Blood. 2024;144:2067. PubMed
HUNTER AM, Patnaik MM, Itzykson R, Mesa R, et al Perspectives on drug development in chronic myelomonocytic leukemia: changing the
paradigm.
Blood. 2024;144:1987-1992. PubMedAbstract available
LOPEZ-MILLAN B, Rubio-Gayarre A, Vinyoles M, Trincado JL, et al NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLLr
B-ALL by regulating NR3C1 expression.
Blood. 2024;144:2002-2017. PubMedAbstract available
VOSO MT, Guarnera L, Lehmann S, Dohner K, et al Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project.
Blood. 2024 Nov 6:blood.2024026186. doi: 10.1182/blood.2024026186. PubMedAbstract available
GUILHOT F, Hehlmann R Long-term Outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia.
Blood. 2024 Nov 1:blood.2024026311. doi: 10.1182/blood.2024026311. PubMedAbstract available
October 2024
LUO MX, Tan T, Trussart M, Poch A, et al Venetoclax Dose Escalation Rapidly Activates a BAFF/BCL-2 Survival Axis in
Chronic Lymphocytic Leukemia.
Blood. 2024 Oct 29:blood.2024024341. doi: 10.1182/blood.2024024341. PubMedAbstract available
WU Q, Chen D Near early T-precursor lymphoblastic leukemia with marked flower petal nuclei:
blast with unique cyanthiform nucleus.
Blood. 2024;144:1846. PubMed
KIM E, Chen SS, Sivina M, Hwang H, et al Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell
kinetics correlate with IGHV, ZAP-70, and MRD.
Blood. 2024 Oct 23:blood.2024025683. doi: 10.1182/blood.2024025683. PubMedAbstract available
LIU Y, Bollino DR, Bah OM, Strovel ET, et al A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for
relapsed/refractory acute myeloid leukemia.
Blood. 2024 Oct 22:blood.2024024837. doi: 10.1182/blood.2024024837. PubMedAbstract available
GOKBUGET N, Steffen B How I Treat Older Patients with Ph/BCR-ABL-Negative Acute Lymphoblastic Leukemia.
Blood. 2024 Oct 11:blood.2023023156. doi: 10.1182/blood.2023023156. PubMedAbstract available
KWOK M, Stankovic T Targeting therapeutic vulnerabilities in T-PLL.
Blood. 2024;144:1548-1550. PubMed
NIEDER R, Li W Constitutive STAT5 activation in precursor B-cell acute lymphoblastic leukemia
with P2RY8::CRLF2 fusion.
Blood. 2024;144:1646. PubMed
VON JAN J, Timonen S, Braun T, Jiang Q, et al Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated
apoptotic responses.
Blood. 2024;144:1595-1610. PubMedAbstract available
SIMONIN M, Vasseur L, Lengline E, Lhermitte L, et al NGS-based stratification refines the risk stratification in T-ALL and identifies
a very-high-risk subgroup of patients.
Blood. 2024;144:1570-1580. PubMedAbstract available
NEWMAN H, Teachey DT A T-ALL order: a new risk classifier for T-ALL.
Blood. 2024;144:1545-1547. PubMed
ROBOZ GJ, Canaani J How I use Maintenance Therapy in Acute Myeloid Leukemia.
Blood. 2024 Oct 7:blood.2024024010. doi: 10.1182/blood.2024024010. PubMedAbstract available
LUSKIN MR, Murakami MA, Keating JH, Flamand Y, et al Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive
acute leukemia.
Blood. 2024 Oct 7:blood.2024025800. doi: 10.1182/blood.2024025800. PubMedAbstract available
ZHOU X, Chen X, Chen J, Wen L, et al Critical role of tripartite fusion and LBD truncation in certain RARA- and all
RARG-related atypical APL.
Blood. 2024;144:1471-1485. PubMedAbstract available
POLONEN P, Mullighan CG, Teachey DT Classification and risk stratification in T-lineage acute lymphoblastic leukemia.
Blood. 2024 Oct 2:blood.2023022920. doi: 10.1182/blood.2023022920. PubMedAbstract available
KYTOLA S, Vanttinen IM, Ruokoranta T, Partanen A, et al Ex Vivo Venetoclax Sensitivity Predicts Clinical Response in Acute Myeloid
Leukemia in the Prospective VenEx Trial.
Blood. 2024 Oct 2:blood.2024024968. doi: 10.1182/blood.2024024968. PubMedAbstract available
GREEN SD, Wang ES How I Treat: Secondary Acute Myeloid Leukemia.
Blood. 2024 Oct 2:blood.2024024011. doi: 10.1182/blood.2024024011. PubMedAbstract available
September 2024
POCOCK R, Mansour MR T-ALL and T-LBL: a notch apart.
Blood. 2024;144:1356-1357. PubMed
LI Z, Meng G Targeting DUX4-r leukemia via PI3K and CD371.
Blood. 2024;144:1354-1356. PubMed
SHARMAN JP Pirtobrutinib combinations in CLL.
Blood. 2024;144:1351-1352. PubMed
THORSSON H, Henningsson R, Puente-Moncada N, Pena-Martinez P, et al Single-cell genomics details the maturation block in BCP-ALL and identifies
therapeutic vulnerabilities in DUX4-r cases.
Blood. 2024;144:1399-1411. PubMedAbstract available
ROEKER LE, Woyach JA, Cheah CY, Coombs CC, et al Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in
relapsed/refractory CLL: the phase 1b BRUIN trial.
Blood. 2024;144:1374-1386. PubMedAbstract available
RAHMAN S, Bloye G, Farah N, Demeulemeester J, et al Focal deletions of a promoter tether activate the IRX3 oncogene in T-cell acute
lymphoblastic leukemia.
Blood. 2024 Sep 24:blood.2024024300. doi: 10.1182/blood.2024024300. PubMedAbstract available
JIN Q, Harris E, Myers JA, Mehmood R, et al Disruption of cotranscriptional splicing suggests that RBM39 is a therapeutic
target in acute lymphoblastic leukemia.
Blood. 2024 Sep 24:blood.2024024281. doi: 10.1182/blood.2024024281. PubMedAbstract available
LOO S, Potter N, Ivey A, O'Nions J Dr, et al Pretransplant MRD detection of fusion transcripts is strongly prognostic in
KMT2A-rearranged acute myeloid leukemia.
Blood. 2024 Sep 24:blood.2024026605. doi: 10.1182/blood.2024026605. PubMedAbstract available
WANG ES Curing APL in Latin America: more than just ATRA.
Blood. 2024;144:1237-1238. PubMed
BONADIES N SHERLOCK unmasks fusion-driven leukemias.
Blood. 2024;144:1241-1243. PubMed
VEDULA RS, Karp HQ, Koob J, Lim F, et al CRISPR-based rapid molecular diagnostic tests for fusion-driven leukemias.
Blood. 2024;144:1290-1299. PubMedAbstract available
PENTER L, Wu CJ Therapy response in AML: a tale of two T cells.
Blood. 2024;144:1134-1136. PubMed
KWON MC, Thuring JW, Querolle O, Dai X, et al Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617
(bleximenib) in KMT2A- and NPM1-altered leukemias.
Blood. 2024;144:1206-1220. PubMedAbstract available
WALTER RB, Potter V, Craddock C Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in
Adults over 70 years old.
Blood. 2024 Sep 6:blood.2024024247. doi: 10.1182/blood.2024024247. PubMedAbstract available
BADAR T, Luger SM, Litzow MR Incorporation of immunotherapy into frontline treatment for adults with B-cell
precursor acute lymphoblastic leukemia.
Blood. 2024 Sep 5:blood.2023022921. doi: 10.1182/blood.2023022921. PubMedAbstract available
SALLMAN DA, Stahl M TP53-Mutated Acute Myeloid Leukemia: How Can We Improve Outcomes?
Blood. 2024 Sep 5:blood.2024024245. doi: 10.1182/blood.2024024245. PubMedAbstract available
EADIE LN, Lagonik E, Page EC, Schutz CE, et al Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires
the ABL SH3 domain for efficacy.
Blood. 2024;144:1022-1026. PubMed
BALDUCCI E, Simonin M, Duployez N, Steimle T, et al Genomic imbalance analysis provides new insight into prognostic factors in adult
and pediatric T-ALL.
Blood. 2024;144:988-1000. PubMedAbstract available
WADHWA A, Chen Y, Hageman L, Angiolillo A, et al Antimetabolite Dose Intensity and Adverse Outcomes in Children with Acute
Lymphoblastic Leukemia: A COG-AALL03N1 Report.
Blood. 2024 Aug 27:blood.2024024455. doi: 10.1182/blood.2024024455. PubMedAbstract available
COBALEDA C, Sanchez-Garcia I Childhood leukemia prevention within reach.
Blood. 2024;144:799-800. PubMed
INGELFINGER F Hijacking T helper cells for AML progression.
Blood. 2024;144:804-805. PubMed
XU Z, Padmore R AML, myelodysplasia related, with STAG2 and SRSF2 comutations with myelocyte
arrest.
Blood. 2024;144:918. PubMed
BHATLA T, Hogan L MD, Teachey DT, Bautista F, et al Daratumumab in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia or
Lymphoblastic Lymphoma: DELPHINUS Study.
Blood. 2024 Aug 16:blood.2024024493. doi: 10.1182/blood.2024024493. PubMedAbstract available
ZHOU X, Zhang L, Aryal S, Veasey V, et al Epigenetic Regulation of Non-canonical Menin Targets Modulates Menin Inhibitor
Response in Acute Myeloid Leukemia.
Blood. 2024 Aug 16:blood.2023023644. doi: 10.1182/blood.2023023644. PubMedAbstract available
HU Z, Ok CY Immature erythroblasts in pleural effusion: an initial presentation of acute
erythroid leukemia in a patient with a history of MDS.
Blood. 2024;144:794. PubMed
ITZYKSON R NPM1-mutated AML: how many diseases?
Blood. 2024;144:681-683. PubMed
OTHMAN J, Potter N, Ivey A, Tazi Y, et al Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.
Blood. 2024;144:714-728. PubMedAbstract available
LEYTE-VIDAL A, Garrido Ruiz D, DeFilippis R, Leske IB, et al BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to
asciminib.
Blood. 2024;144:639-645. PubMedAbstract available
YEUNG DT, Shanmuganathan N, Reynolds J, Branford S, et al Asciminib Monotherapy as Frontline Treatment of Chronic-Phase Chronic Myeloid
Leukemia: Results from the ASCEND Study.
Blood. 2024 Aug 5:blood.2024024657. doi: 10.1182/blood.2024024657. PubMedAbstract available
ARRIETA-BOLANOS E, van der Burg LLJ, Gedde-Dahl T, Robin M, et al Directionality of HLA-DP permissive mismatches improves risk prediction in HCT
for acute leukemia and MDS.
Blood. 2024 Aug 5:blood.2024024351. doi: 10.1182/blood.2024024351. PubMedAbstract available
Metzeler KH, Herold T, Rothenberg-Turley M, et al. Spectrum and prognostic
relevance of driver gene mutations in acute myeloid leukemia. Blood.
2016;128(5):686-698.
Blood. 2024;144:589. PubMed
MOSS P A tumor suppressor of CLL: all (T-)bets are on.
Blood. 2024;144:467-469. PubMed
COOK JA, Lott L, Perry J, Eckel AM, et al Fusion-harboring mast cells can explain molecular positivity in flow cytometric
MRD-negative core-binding factor AML.
Blood. 2024;144:581-585. PubMedAbstract available
EFFICACE F, Kicinski M, Coens C, Suciu S, et al Decitabine in older patients with AML: quality of life results of the
EORTC-GIMEMA-GMDS-SG randomized phase 3 trial.
Blood. 2024;144:541-551. PubMedAbstract available
July 2024
ZHANG X, Liu B, Huang J, Zhang YL, et al A predictive model for therapy failure in chronic myeloid leukemia patients
receiving tyrosine kinase inhibitor therapy.
Blood. 2024 Jul 24:blood.2024024761. doi: 10.1182/blood.2024024761. PubMedAbstract available
TE VRUGT M, Wessolowski JS, Randau G, Alfert A, et al Pediatric T-cell lymphoblastic lymphoma but not leukemia harbor TRB::NOTCH1
fusions with unfavorable outcome.
Blood. 2024 Jul 18:blood.2024025307. doi: 10.1182/blood.2024025307. PubMedAbstract available
van der Straten L, Stege CAM, Kersting S, et al. Fixed-duration venetoclax plus
obinutuzumab improves quality of life and geriatric impairments in FCR-unfit
patients with CLL. Blood. 2023;142(13):1131-1142.
Blood. 2024;144:341. PubMed
Melnick AF, Mullin C, Lin K, et al. Cdc73 protects Notch-induced T-cell leukemia
cells from DNA damage and mitochondrial stress. Blood. 2023;142(25):2159-2174.
Blood. 2024;144:342. PubMed
RADICH J Transplant, MRD, and predicting relapse in AML.
Blood. 2024;144:245-247. PubMed
OPAT S Treatment of relapsed CLL "in the BAAG"?
Blood. 2024;144:243-244. PubMed
MUFFLY L, Liang EC, Dolan JG, Pulsipher MA, et al How I use next-generation sequencing-MRD to plan approach and prevent relapse
after HCT for children and adults with ALL.
Blood. 2024;144:253-261. PubMedAbstract available
FURSTENAU M, Giza A, Weiss J, Kleinert F, et al Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final
efficacy and ctDNA analysis of the CLL2-BAAG trial.
Blood. 2024;144:272-282. PubMedAbstract available
WEI Q, Xu J Chronic eosinophilic leukemia with a novel JAK1 mutation responds well to the
JAK1/2 inhibitor ruxolitinib.
Blood. 2024;144:238. PubMed
HOURIGAN CS How complete must an AML remission be?
Blood. 2024;144:131-132. PubMed
AL-SAWAF O, Robrecht S, Zhang C, Olivieri S, et al Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia:
6-year results of the phase 3 CLL14 study.
Blood. 2024 Jul 10:blood.2024024631. doi: 10.1182/blood.2024024631. PubMedAbstract available
ISSA GC, Stein EM, DiNardo CDD How I Treat: Differentiation Therapy in Acute Myeloid Leukemia.
Blood. 2024 Jul 8:blood.2024024008. doi: 10.1182/blood.2024024008. PubMedAbstract available
SUO S, Zhao D, Li F, Zhang Y, et al Homoharringtonine Inhibits the NOTCH/MYC Pathway and Exhibits Anti-Tumor Effects
in T-Cell Acute Lymphoblastic Leukemia.
Blood. 2024 Jul 5:blood.2023023400. doi: 10.1182/blood.2023023400. PubMedAbstract available
SRINAGESH HK, Jackson C, Shiraz P, Jeyakumar N, et al A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for
Refractory B-cell Acute Lymphoblastic Leukemia.
Blood. 2024 Jul 5:blood.2024024952. doi: 10.1182/blood.2024024952. PubMedAbstract available
LUM SH, Eikema DJ, Piepenbroek B, Wynn R, et al Outcome of Hematopoietic Stem Cell Transplantation in 813 Pediatric Patients with
Fanconi Anemia.
Blood. 2024 Jul 5:blood.2023022751. doi: 10.1182/blood.2023022751. PubMedAbstract available
QIAN Z, Yu F GADD45A: a key tumor suppressor in AML subtypes.
Blood. 2024;144:6-7. PubMed
ZHAO Y, Short NJ, Kantarjian HM, Chang TC, et al Genomic determinants of response and resistance to inotuzumab ozogamicin in
B-cell ALL.
Blood. 2024;144:61-73. PubMedAbstract available
June 2024
RADPOUR R, Simillion C, Wang B, Abbas HA, et al IL-9 Secreted by Leukemia Stem Cells Induces Th1-Skewed CD4+ T-Cells, which
Promote Their Expansion.
Blood. 2024 Jun 28:blood.2024024000. doi: 10.1182/blood.2024024000. PubMedAbstract available
BIDOT S, Feldman AL Herpetic lymphadenitis mimicking Richter transformation of chronic lymphocytic
leukemia/small lymphocytic lymphoma.
Blood. 2024;143:2808. PubMed
LENK L, Baccelli I, Laqua A, Heymann J, et al The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via
antibody-dependent cellular phagocytosis.
Blood. 2024;143:2735-2748. PubMedAbstract available
LIN HY, Mohammadhosseini M, McClatchy J, Villamor-Paya M, et al The TLK-ASF1 histone chaperone pathway plays a critical role in IL-1beta-mediated
AML progression.
Blood. 2024;143:2749-2762. PubMedAbstract available
WALCZAK P, Fodil S, Vignal N, Cabannes-Hamy A, et al Cerebrospinal fluid distribution and pharmacokinetics of ponatinib in
Ph1-positive acute lymphoblastic leukemia.
Blood. 2024 Jun 25:blood.2024024838. doi: 10.1182/blood.2024024838. PubMedAbstract available
BARTRAM J, Ancliff P, Vora A How I Treat on Infant Acute Lymphoblastic Leukemia.
Blood. 2024 Jun 21:blood.2023023154. doi: 10.1182/blood.2023023154. PubMedAbstract available
Garcia E, Horowitz AM, Franklin K, Mader M, Kaur S. Outcomes of veterans with
FMS-like tyrosine kinase 3 mutated (mFLT3) acute myeloid leukemia (AML) treated
with novel FLT3 inhibitors (FLT3i) within the Veterans Health Administration
(VHA) [abstract]
Blood. 2024;143:2676. PubMed
FORCONI F Time for a new prognostic score in CLL?
Blood. 2024;143:2561-2562. PubMed
GAO Q, Harrison CJ B-ALL with intrachromosomal amplification of chromosome 21 in a carrier of the
Robertsonian translocation rob(14;21)c.
Blood. 2024;143:2672. PubMed
SATO T, Yoshida K, Toki T, Kanezaki R, et al Landscape of driver mutations and their clinical effects on Down syndrome-related
myeloid neoplasms.
Blood. 2024;143:2627-2643. PubMedAbstract available
FARROKHI A, Atre T, Salitra S, Aletaha M, et al Early-life infection depletes preleukemic cells in a mouse model of hyperdiploid
B-cell acute lymphoblastic leukemia.
Blood. 2024 Jun 14:blood.2024025038. doi: 10.1182/blood.2024025038. PubMedAbstract available
SANZ J, Labopin M, Choi G, Kulagin A, et al Younger unrelated donors may be preferable over HLA match in the PTCy era: a
study from the ALWP of the EBMT.
Blood. 2024;143:2534-2543. PubMedAbstract available
MARCHAND T, Lamy de La Chapelle T, Loughran TP A modern view of LGL leukemia.
Blood. 2024 Jun 7:blood.2023021790. doi: 10.1182/blood.2023021790. PubMedAbstract available
LUSKIN MR Finding the perPh+ect balance in Ph+ ALL.
Blood. 2024;143:2339-2340. PubMed
May 2024
KANG YA Awakening your innate power to combat AML.
Blood. 2024;143:2223-2224. PubMed
HALL T, Gurbuxani S, Crispino JD Malignant progression of preleukemic disorders.
Blood. 2024;143:2245-2255. PubMedAbstract available
ONIDA F, Gagelmann N, Chalandon Y, Kobbe G, et al Management of adult patients with CMML undergoing allo-HCT: recommendations from
the EBMT PH&G Committee.
Blood. 2024;143:2227-2244. PubMedAbstract available
KOURY LCA, Kim HT, Undurraga MS, Navarro-Cabrera JR, et al Clinical networking results in continuous improvement of the outcome of patients
with acute promyelocytic leukemia.
Blood. 2024 May 28:blood.2024023890. doi: 10.1182/blood.2024023890. PubMedAbstract available
BRINKMANN BJ, Floerchinger A, Schniederjohann C, Roider T, et al CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma
in-vitro and CLL in-vivo models.
Blood. 2024 May 28:blood.2023022682. doi: 10.1182/blood.2023022682. PubMedAbstract available
SAWYER EM, Kraft AS SMACing down relapsed T-ALL.
Blood. 2024;143:2116-2117. PubMed
MAZZIOTTA F, Biavati L, Rimando JC, Rutella S, et al CD8+ T-cell Differentiation and Dysfunction Inform Treatment Response in Acute
Myeloid Leukemia.
Blood. 2024 May 22:blood.2023021680. doi: 10.1182/blood.2023021680. PubMedAbstract available
LEWIS RI, Vom Stein AF, Hallek MJ Targeting the tumor microenvironment for treating double refractory chronic
lymphocytic leukemia.
Blood. 2024 May 22:blood.2023022861. doi: 10.1182/blood.2023022861. PubMedAbstract available
WOYACH JA, Jones D, Jurczak W, Robak T Prof, et al Mutational profile of previously treated chronic lymphocytic leukemia patients
progressing on acalabrutinib or ibrutinib.
Blood. 2024 May 16:blood.2023023659. doi: 10.1182/blood.2023023659. PubMedAbstract available
MRD and EFS in pediatric T-lymphoblastic lymphoma.
Blood. 2024;143:2111. PubMed
Silva A, Almeida ARM, Cachucho A, et al. Overexpression of wild-type IL-7Ralpha
promotes T-cell acute lymphoblastic leukemia/lymphoma. Blood.
2021;138(12):1040-1052.
Blood. 2024;143:2108-2110. PubMed
RIBERA JM MRD: also for T-lymphoblastic lymphoma.
Blood. 2024;143:2017-2019. PubMed
TAMENI A, Toffalori C, Vago L Tricking the Trickster: Precision Medicine Approaches to Counteract Leukemia
Immune Escape after Transplant.
Blood. 2024 May 10:blood.2023019962. doi: 10.1182/blood.2023019962. PubMedAbstract available
LE RQ, Przepiorka D, Chen H, Shen YL, et al Complete Remission with Partial Hematological Recovery as a Palliative Endpoint
for Treatment of Acute Myeloid Leukemia.
Blood. 2024 May 10:blood.2023023313. doi: 10.1182/blood.2023023313. PubMedAbstract available
RECHER C Transplant in AML: just follow the NPM1 guide!
Blood. 2024;143:1881-1882. PubMed
SUNG PJ PIKing the right target in AML.
Blood. 2024;143:1884-1885. PubMed
OTHMAN J, Potter N, Ivey A, Jovanovic J, et al Postinduction molecular MRD identifies patients with NPM1 AML who benefit from
allogeneic transplant in first remission.
Blood. 2024;143:1931-1936. PubMedAbstract available
GOKBUGET N, Boissel N, Chiaretti S, Dombret H, et al Management of ALL in adults: 2024 ELN recommendations from a European expert
panel.
Blood. 2024;143:1903-1930. PubMedAbstract available
GOKBUGET N, Boissel N, Chiaretti S, Dombret H, et al Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN
recommendations from a European expert panel.
Blood. 2024;143:1891-1902. PubMedAbstract available
April 2024
ROESSNER PM, Seufert I, Chapaprieta V, Jayabalan R, et al T-bet suppresses proliferation of malignant B cells in chronic lymphocytic
leukemia.
Blood. 2024 Apr 29:blood.2023021990. doi: 10.1182/blood.2023021990. PubMedAbstract available
KRAKOW EF, Brault M, Summers C, Cunningham TM, et al HA-1-targeted T cell receptor (TCR) T cell therapy for recurrent leukemia after
hematopoietic stem cell transplantation.
Blood. 2024 Apr 29:blood.2024024105. doi: 10.1182/blood.2024024105. PubMedAbstract available
WIENECKE CP, Heida B, Venturini L, Gabdoulline R, et al Clonal Relapse Dynamics in Acute Myeloid Leukemia Following Allogeneic
Hematopoietic Cell Transplantation.
Blood. 2024 Apr 26:blood.2023022697. doi: 10.1182/blood.2023022697. PubMedAbstract available
SUBKLEWE M T cells take aim in AML: targeting IDH2.
Blood. 2024;143:1681-1682. PubMed
ABDELBAKY SB, Giacopelli B, Rabe KG, Yamaguchi K, et al Prediction of outcomes for high-count monoclonal B lymphocytosis using an
epigenetic and immunogenetic signature.
Blood. 2024;143:1752-1757. PubMedAbstract available
TRAN TH, Tasian SK How I Treat Philadelphia Chromosome-like Acute Lymphoblastic Leukemia in
Children, Adolescents, and Young Adults.
Blood. 2024 Apr 24:blood.2023023153. doi: 10.1182/blood.2023023153. PubMedAbstract available
LAMBLE AJ, Rau RE IFN-gamma and CD38 in AML: a T-cell engagement made in heaven?
Blood. 2024;143:1556-1557. PubMed
CUNEO A, Ghia P Ibrutinib in CLL: benefit for all?
Blood. 2024;143:1558-1559. PubMed
BUFFET R How lipid coating soothes the gut in AML therapy.
Blood. 2024;143:1559-1561. PubMed
RENGA G, Nunzi E, Stincardini C, Pariano M, et al CPX-351 exploits the gut microbiota to promote mucosal barrier function,
colonization resistance, and immune homeostasis.
Blood. 2024;143:1628-1645. PubMedAbstract available
WOYACH JA, Perez Burbano G, Ruppert AS, Miller C, et al Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens
for older adults with CLL.
Blood. 2024;143:1616-1627. PubMedAbstract available
LANGERBEINS P, Giza A, Robrecht S, Cramer P, et al Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in
the era of targeted therapies.
Blood. 2024 Apr 15:blood.2023022564. doi: 10.1182/blood.2023022564. PubMedAbstract available
BULLINGER L, Kronke J Making AML fly too close to the sun.
Blood. 2024;143:1438-1439. PubMed
BOURGEOIS W, Cutler JA, Aubrey BJ, Wenge DV, et al Mezigdomide is effective alone and in combination with menin inhibition in
preclinical models of KMT2A-r and NPM1c AML.
Blood. 2024;143:1513-1527. PubMedAbstract available
KROEZE E, Iaccarino I, Kleisman MM, Mondal M, et al Mutational and transcriptional landscape of pediatric B-cell precursor
lymphoblastic lymphoma.
Blood. 2024 Apr 8:blood.2024023938. doi: 10.1182/blood.2024023938. PubMedAbstract available
HASSAN N, Yi H, Malik B, Gaspard-Boulinc LC, et al Loss of stress sensor GADD45A promotes stem cell activity and ferroptosis
resistance in LGR4/HOXA9-dependent AML.
Blood. 2024 Apr 5:blood.2024024072. doi: 10.1182/blood.2024024072. PubMedAbstract available
MARCAIS A Targeting PD-L1 to treat ATLL?
Blood. 2024;143:1320-1322. PubMed
MINA A, Greenberg PL, Deeg HJ How I reduce and treat posttransplant relapse of MDS.
Blood. 2024;143:1344-1354. PubMedAbstract available
BASTIAN L, Beder T, Barz MJ, Bendig S, et al Developmental trajectories and cooperating genomic events define molecular
subtypes of BCR::ABL1-positive ALL.
Blood. 2024;143:1391-1398. PubMedAbstract available
March 2024
INESS AN, Bachireddy P GPR56 in GVL: marker or mechanism?
Blood. 2024;143:1206-1207. PubMed
MATHIOUDAKI A, Wang X, Sedloev D, Huth R, et al The remission status of AML patients after allo-HCT is associated with a distinct
single-cell bone marrow T-cell signature.
Blood. 2024;143:1269-1281. PubMedAbstract available
BAUMGARTNER F, Baer C, Bamopoulos S, Ayoub E, et al Comparing malignant monocytosis across the updated WHO and ICC classifications of
2022.
Blood. 2024;143:1139-1156. PubMedAbstract available
KLEIN K, Kollmann S, Hiesinger A, List J, et al A lineage-specific STAT5BN642H mouse model to study NK-cell leukemia.
Blood. 2024 Mar 18:blood.2023022655. doi: 10.1182/blood.2023022655. PubMedAbstract available
AZOULAY E, Maertens J, Lemiale V How I manage acute respiratory failure in patients with hematological
malignancies.
Blood. 2024;143:971-982. PubMedAbstract available
MACK EA, Dougher MC, Ginda AM, Cahill C, et al Red cell exchange for rapid leukoreduction in adults with hyperleukocytosis and
leukostasis.
Blood. 2024;143:1049-1054. PubMedAbstract available
FELIPE FUMERO E, Walter C, Frenz JM, Seifert FC, et al Epigenetic control over cell-intrinsic immune response antagonizes self-renewal
in acute myeloid leukemia.
Blood. 2024 Mar 8:blood.2023021640. doi: 10.1182/blood.2023021640. PubMedAbstract available
HAYASHI RJ, Hermiston ML, Wood BL, Teachey DT, et al MRD at the End of Induction and EFS in T-cell Lymphoblastic Lymphoma: Children's
Oncology Group Trial AALL1231.
Blood. 2024 Mar 8:blood.2023021184. doi: 10.1182/blood.2023021184. PubMedAbstract available
CHALANDON Y, Rousselot P, Chevret S, Cayuela JM, et al Nilotinib with or without cytarabine for Philadelphia positive acute
lymphoblastic leukemia.
Blood. 2024 Mar 7:blood.2023023502. doi: 10.1182/blood.2023023502. PubMedAbstract available
AHMED R, Feldman AL Occult ALK-negative anaplastic large cell lymphoma complicating chronic
lymphocytic leukemia.
Blood. 2024;143:938. PubMed
O'CONNOR D, Valle-Inclan JE, Conde L, Bloye G, et al Noncoding mutations drive persistence of a founder preleukemic clone which
initiates late relapse in T-ALL.
Blood. 2024;143:933-937. PubMedAbstract available
ESCHERICH CS, Chen W, Li Y, Yang W, et al Germline Genetic NBN Variation and Predisposition to B-cell Acute Lymphoblastic
Leukemia in Children.
Blood. 2024 Mar 6:blood.2023023336. doi: 10.1182/blood.2023023336. PubMedAbstract available
AVILA AVILA A, Nuantang K, Oliveira ML, Druillennec S, et al Targeting the TNF/IAP pathway synergizes with anti-CD3 immunotherapy in T-Cell
Acute Lymphoblastic Leukemia.
Blood. 2024 Mar 4:blood.2023022455. doi: 10.1182/blood.2023022455. PubMedAbstract available
February 2024
BARROS PINTO MP, Cabecadas J Binucleated and cloverleaf-shaped nucleus in lymphocytes in CLL.
Blood. 2024;143:833. PubMed
MURTADHA M, Park M, Zhu Y, Caserta E, et al CD38-directed, single-chain T cell-engager targets leukemia stem cells through
IFNgamma-induced CD38 expression.
Blood. 2024 Feb 26:blood.2023021570. doi: 10.1182/blood.2023021570. PubMedAbstract available
VAN OUTERSTERP I, Tasian SK, Reichert CE, Boeree A, et al Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: The
role of kinase type and SH3 domain.
Blood. 2024 Feb 23:blood.2023023120. doi: 10.1182/blood.2023023120. PubMedAbstract available
BARBOSA K, Deshpande A, Perales M, Xiang P, et al Transcriptional control of leukemogenesis by the chromatin reader SGF29.
Blood. 2024;143:697-712. PubMedAbstract available
BISWAS J, Abdel-Wahab O A new SAGA for AML: targeting SGF29 in AML.
Blood. 2024;143:657-658. PubMed
SUMMERS RJ, Teachey DT, Hunger SP How I treat early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) in
children.
Blood. 2024 Feb 16:blood.2023023155. doi: 10.1182/blood.2023023155. PubMedAbstract available
MENSURADO S, Condeco AC, Sanchez-Martinez D, Shirley S, et al CD155/PVR determines Acute Myeloid Leukemia targeting by Delta One T cells.
Blood. 2024 Feb 16:blood.2023022992. doi: 10.1182/blood.2023022992. PubMedAbstract available
FISKUS W, Piel J, Collins MP, Hentemann M, et al BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical
efficacy combined with BET or Menin inhibitor.
Blood. 2024 Feb 16:blood.2023022832. doi: 10.1182/blood.2023022832. PubMedAbstract available
COTY-FATTAL Z, Richardson AI A 3-year-old with chronic myeloid leukemia.
Blood. 2024;143:651. PubMed
BARAJAS JM, Rasouli M, Umeda M, Hiltenbrand R, et al Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin
inhibitors.
Blood. 2024;143:619-630. PubMedAbstract available
BERNT KM Menin dependence: UBTF-ITD AML joins the club.
Blood. 2024;143:567-569. PubMed
CHEN B, Abdel-Wahab O Targeting the cBAF complex in T-ALL.
Blood. 2024;143:566-567. PubMed
ARBER C Two to tango: engineered T cells against AML.
Blood. 2024;143:476-478. PubMed
QIU L, Naresh KN Mature plasmacytoid dendritic cell proliferation in association with
mixed-phenotype acute leukemia, T/myeloid.
Blood. 2024;143:561. PubMed
DAO T, Xiong G, Mun SS, Meyerberg J, et al A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves
specificity and potency against AML.
Blood. 2024;143:507-521. PubMedAbstract available
BHATT VR, Uy GL, Klepin HD Determining treatment tolerance and fitness for intensive chemotherapy in older
adults with AML: a call to action.
Blood. 2024;143:483-487. PubMedAbstract available
ROUSSELOT P Old rivals become new friends.
Blood. 2024;143:380-382. PubMed
ORDONEZ MAZARIEGOS EE, Dimopoulos YP A rare case of ICUS progressing to MDS with isolated isochromosome 17q and AML.
Blood. 2024;143:473. PubMed
January 2024
GU H, Chen C, Hou ZS, He XD, et al PI3Kgamma maintains the self-renewal of acute myeloid leukemia stem cells by
regulating the pentose phosphate pathway.
Blood. 2024 Jan 25:blood.2023022202. doi: 10.1182/blood.2023022202. PubMedAbstract available
SCHRAW JM Anticancer drug exposure in utero and leukemia.
Blood. 2024;143:293-294. PubMed
BARATA JT Darwin, MSI2, and relapse in T-ALL.
Blood. 2024;143:294-296. PubMed
SAHASRABUDHE KD, Mims AS MRD in AML: who, what, when, where, and how?
Blood. 2024;143:296-298. PubMed
OTHMAN J, Tiong IS, O'Nions J, Dennis M, et al Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving
venetoclax-based nonintensive therapy.
Blood. 2024;143:336-341. PubMedAbstract available
LEUNG WK, Torres Chavez AG, French-Kim M, Shafer P, et al Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia.
Blood. 2024 Jan 19:blood.2023021979. doi: 10.1182/blood.2023021979. PubMedAbstract available
WEINACHT KG The rise of haplo: a quest for the perfect graft.
Blood. 2024;143:193-195. PubMed
alphabetaT/CD19-depleted haploHSCT for pediatric leukemia.
Blood. 2024;143:291. PubMed
CHEN H, Wang H Acute myeloid leukemia with GATA2 and WT1 mutations mimicking acute promyelocytic
leukemia.
Blood. 2024;143:290. PubMed
SAULTIER P, Michel G How I Treat: long-term survivors of childhood acute leukemia.
Blood. 2024 Jan 16:blood.2023019804. doi: 10.1182/blood.2023019804. PubMedAbstract available
BULDINI B, Varotto E, Maurer-Granofszky M, Gaipa G, et al CD371+ pediatric B-cell acute lymphoblastic leukemia: propensity to lineage
switch and slow early response to treatment.
Blood. 2024 Jan 12:blood.2023021952. doi: 10.1182/blood.2023021952. PubMedAbstract available
Bamezai S, Pulikkottil AJ, Yadav T, et al. A noncanonical enzymatic function of
PIWIL4 maintains genomic integrity and leukemic growth in AML. Blood.
2023;142(1):90-105.
Blood. 2024;143:184. PubMed
DIMOPOULOS YP, Loghavi S Acute leukemia of ambiguous lineage with BCL11B rearrangement.
Blood. 2024;143:183. PubMed
GHORASHIAN S, Lucchini G, Richardson R, Nguyen K, et al CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative
relapse after CAR T-cell therapy for B-cell ALL.
Blood. 2024;143:118-123. PubMedAbstract available
VELTMAAT L, Cortes J Arterio-Occlusive Events Among Patients with Chronic Myeloid Leukemia on Tyrosine
Kinase Inhibitors.
Blood. 2024 Jan 9:blood.2023022403. doi: 10.1182/blood.2023022403. PubMedAbstract available
MOSS P Ibrutinib reversal of immune exhaustion in CLL.
Blood. 2024;143:5-7. PubMed
Kennedy E, Coulter E, Halliwell E, et al. TLR9 expression in chronic lymphocytic
leukemia identifies a promigratory subpopulation and novel therapeutic target.
Blood. 2021;137(22):3064-3078.
Blood. 2024;143:93. PubMed
PAPAZOGLOU D, Wang XV, Shanafelt TD, Lesnick CE, et al Ibrutinib-based therapy reinvigorates CD8+ T cells compared to
chemoimmunotherapy: immune monitoring from the E1912 trial.
Blood. 2024;143:57-63. PubMedAbstract available
December 2023
QUESSADA J, Loosveld M CBFB::MYH11 fusion in a nonmonocytic acute myeloid leukemia.
Blood. 2023;142:2332. PubMed
HASSERJIAN RP, Germing U, Malcovati L Diagnosis and classification of myelodysplastic syndromes.
Blood. 2023;142:2247-2257. PubMedAbstract available
DEZERN AE, Greenberg PL The trajectory of prognostication and risk stratification for patients with
myelodysplastic syndromes.
Blood. 2023;142:2258-2267. PubMedAbstract available
CHIBA M, Shimono J, Suto K, Ishio T, et al Whole genome CRISPR screening identifies molecular mechanisms of PD-L1 expression
in Adult T-cell leukemia/lymphoma.
Blood. 2023 Dec 24:blood.2023021423. doi: 10.1182/blood.2023021423. PubMedAbstract available
BRECCIA M A traffic light for TFR by lineage-specific MRD.
Blood. 2023;142:2129-2130. PubMed
FU L, Gong S KMT2A-rearranged B-lymphoblastic leukemia/lymphoma with surface light chain
restriction and lacking immature markers.
Blood. 2023;142:2220. PubMed
NIH natural history study of FPDMM patients.
Blood. 2023;142:2222. PubMed
FRANK D, Patnana PK, Vorwerk J, Mao L, et al Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA
damage and repair therapy.
Blood. 2023;142:2175-2191. PubMedAbstract available
CUNNINGHAM L, Merguerian M, Calvo KR, Davis J, et al Natural history study of patients with familial platelet disorder with associated
myeloid malignancy.
Blood. 2023;142:2146-2158. PubMedAbstract available
MARCELLINO BK PPM1D inhibition may allow us to WIP leukemia.
Blood. 2023;142:2040-2042. PubMed
COUSTAN-SMITH E, Conter V Closing the circle for ETP ALL.
Blood. 2023;142:2039-2040. PubMed
WOOD BL, Devidas M, Summers RJ, Chen Z, et al Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a
Children's Oncology Group study.
Blood. 2023;142:2069-2078. PubMedAbstract available
DIMITRIOU M, Mortera-Blanco T, Tobiasson M, Mazzi S, et al Identification and surveillance of rare relapse-initiating stem cells during
complete remission post-transplantation.
Blood. 2023 Dec 14:blood.2023022851. doi: 10.1182/blood.2023022851. PubMedAbstract available
PALM-APERGI C PLK4, a potential target against AML.
Blood. 2023;142:1941-1942. PubMed
STONE RM FLT(3)-ing about: the search for the best inhibitor.
Blood. 2023;142:1937-1938. PubMed
MAN CH, Lam W, Dang CC, Zeng XY, et al Inhibition of PLK4 remodels histone methylation and activates the immune response
via the cGAS-STING pathway in TP53-mutated AML.
Blood. 2023;142:2002-2015. PubMedAbstract available
FLEMING S, Tsai XC, Morris R, Hou HA, et al TP53 status and impact on AML prognosis within the ELN 2022 risk classification.
Blood. 2023;142:2029-2033. PubMedAbstract available
LOO S, Roberts AW, Anstee NS, Kennedy GA, et al Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a
randomized, placebo-controlled study by the ALLG.
Blood. 2023;142:1960-1971. PubMedAbstract available
November 2023
BEWERSDORF JP, How J, Masarova L, Bose P, et al Moving toward disease modification in polycythemia vera.
Blood. 2023;142:1859-1870. PubMedAbstract available
DAVIDS MS Functional cure reported in CLL.
Blood. 2023;142:1761-1763. PubMed
LIN E, Chen W Acute myeloid leukemia with NUP98::HOXA9 mimicking acute promyelocytic leukemia.
Blood. 2023;142:1845. PubMed
Wei AH, Panayiotidis P, Montesinos P, et al. Long-term follow-up of VIALE-C in
patients with untreated AML ineligible for intensive chemotherapy. Blood.
2022;140(25):2754-2756.
Blood. 2023;142:1846-1847. PubMed
THOMPSON PA, Bazinet A, Wierda WG, Tam CS, et al Sustained remissions in CLL after frontline FCR treatment with very-long-term
follow-up.
Blood. 2023;142:1784-1788. PubMedAbstract available
KIM R, Bergugnat H, Pastoret C, Pasquier F, et al Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell
precursor ALL in adults: a GRAALL study.
Blood. 2023;142:1806-1817. PubMedAbstract available
ROLLIG C Gemtuzumab ozogamicin in AML: the next chapter.
Blood. 2023;142:1673-1674. PubMed
STRASSER B, Haushofer A Cabot rings in chronic myelomonocytic leukemia.
Blood. 2023;142:1757. PubMed
FREEMAN SD, Thomas A, Thomas I, Hills RK, et al Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in
older patients with AML: the UK NCRI AML18 trial.
Blood. 2023;142:1697-1707. PubMedAbstract available
Fractionated vs single-dose gemtuzumab for AML.
Blood. 2023;142:1759. PubMed
BUENO C, Torres-Ruiz R, Velasco-Hernandez T, Molina O, et al A human genome editing-based MLL::AF4 ALL model recapitulates key cellular and
molecular leukemogenic features.
Blood. 2023;142:1752-1756. PubMedAbstract available
THOL FR, Dohner H, Ganser A How I treat refractory and relapsed acute myeloid leukemia.
Blood. 2023 Nov 9:blood.2023022481. doi: 10.1182/blood.2023022481. PubMedAbstract available
VYAS P Changing treatment changing prognosis of mutations.
Blood. 2023;142:1583-1585. PubMed
AOKI K, Hyuga M, Tarumoto Y, Nishibuchi G, et al Canonical BAF complex regulates the oncogenic program in human T-cell acute
lymphoblastic leukemia.
Blood. 2023 Nov 3:blood.2023020857. doi: 10.1182/blood.2023020857. PubMedAbstract available
October 2023
JABBOUR EJ, Haddad FG, Short NJ, Senapati J, et al Phase II Study of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute
Lymphoblastic Leukemia in Remission.
Blood. 2023 Oct 25:blood.2023022330. doi: 10.1182/blood.2023022330. PubMedAbstract available
PRINCE HM Blocked addiction to IL-15 for treating T-LGLL.
Blood. 2023;142:1258-1260. PubMed
XIE J, Bao X, Xue SL, Shen H, et al Venetoclax with decitabine as frontline treatment in younger adults with newly
diagnosed ELN adverse-risk AML.
Blood. 2023;142:1323-1327. PubMed
ZHANG J, Duan Y, Wu P, Chang Y, et al Clonal Evolution Dissection Reveals High MSI2 Level Promotes Chemo-resistance in
T-cell Acute Lymphoblastic Leukemia.
Blood. 2023 Oct 6:blood.2023020490. doi: 10.1182/blood.2023020490. PubMedAbstract available
KUMAR J, Petrova-Drus K Acute leukemia with predominantly myeloid differentiation and TBL1XR1::CSF1R
fusion.
Blood. 2023;142:1253. PubMed
CHELOOR KOVILAKAM S, Gu M, Dunn WG, Marando L, et al Prevalence and significance of DDX41 gene variants in the general population.
Blood. 2023;142:1185-1192. PubMedAbstract available
YAMAMOTO S, Sanefuji M, Suzuki M, Sonoda Y, et al Pediatric leukemia and maternal occupational exposure to anticancer drugs: The
Japan Environment and Children's Study.
Blood. 2023 Oct 3:blood.2023021008. doi: 10.1182/blood.2023021008. PubMedAbstract available
September 2023
GOEDE V Frailty is also a target for targeted drugs in CLL.
Blood. 2023;142:1107-1108. PubMed
VAN DER STRATEN L, Stege CAM, Kersting S, Nasserinejad K, et al Fixed-duration venetoclax plus obinutuzumab improves quality of life and
geriatric impairments in FCR-unfit patients with CLL.
Blood. 2023;142:1131-1142. PubMedAbstract available
MERLI P, Algeri M, Galaverna F, Bertaina V, et al TCRalphabeta/CD19 cell-depleted HLA-haploidentical transplantation to treat pediatric
acute leukemia: updated final analysis.
Blood. 2023 Sep 22:blood.2023021336. doi: 10.1182/blood.2023021336. PubMedAbstract available
LI S, Adams PD Targeting the epichaperome to combat AML.
Blood. 2023;142:1031-1032. PubMed
Gribben JG. Targeting the methylome to improve CLL outcome. Blood.
2023;142(1):4-6.
Blood. 2023;142:1103. PubMed
CARTER BZ, Mak PY, Muftuoglu M, Tao W, et al Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells.
Blood. 2023;142:1056-1070. PubMedAbstract available
KWOK M, Stankovic T CLL patients: GIVe me three!
Blood. 2023;142:941-943. PubMed
HUBER H, Tausch E, Schneider C, Edenhofer S, et al Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax
for untreated CLL with del(17p)/TP53mut.
Blood. 2023;142:961-972. PubMedAbstract available
BENNETT J, Ishikawa C, Agarwal P, Yeung J, et al Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in
MDS/AML.
Blood. 2023;142:989-1007. PubMedAbstract available
FEI MY, Wang Y, Chang BH, Xue K, et al The non-cell-autonomous function of ID1 promotes AML progression via ANGPTL7 from
the microenvironment.
Blood. 2023;142:903-917. PubMedAbstract available